JW
Therapeutic Areas
AvantGen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Anti-CD16a NK Cell Engager Platform | Oncology (via NK cell engagement) | Pre-clinical |
| Partner Program - ADRX-0706 (with Adcentrx) | Advanced Solid Tumors (Nectin-4 ADC) | Phase 1 |
| Partner Program - CAR-T Therapy (with Kite) | Unspecified Oncology | Phase 1 |